Myelodysplastic Syndrome — Trials

Myelodysplastic Syndrome — Trials · CancerIndex

Clinical trials

Registered studies

1,702 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 336
Recruiting: 196
Ph III recruiting: 9
Growth YoY: +2.1%
Industry share: 20%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 33.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (307)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06398457	Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies	recruiting	Early Phase 1	8	Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER	1	Sep 24, 2026	clinicaltrials
NCT06765876	CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial(UHKT-CAR123-01)	active not recruiting	Early Phase 1	18	Institute of Hematology and Blood Transfusion, Czech Republic